MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel and bio-therapeutic solutions for tissue repair and regeneration. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was founded in 2000 and is headquartered in Yavne, Israel.
P/B ratio for MediWound Ltd. (MDWD)
P/B ratio as of 2023: 2.90
According to MediWound Ltd.'s latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 2.90. At the end of 2022 the company had a P/B ratio of 6.16.
P/B ratio history for MediWound Ltd. from 2011 to 2023
P/B ratio at the end of each year
| Year | P/B ratio |
|---|---|
| 2023 | 2.90 |
| 2022 | 6.16 |
| 2021 | -14.03 |
| 2020 | 13.84 |
| 2019 | 5.55 |
| 2018 | 12.27 |
| 2017 | 11.04 |
| 2016 | 12.88 |
| 2015 | 7.89 |
| 2014 | 3.09 |
| 2013 | -17.75 |
| 2012 | 22.48 |
| 2011 | 0.00 |